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with schizophrenia. Methods: Two methods exist to assess MCID in scales such 
as CDSS: the anchor-based approach (comparison of the change in CDSS score and 
Clinical Global Impression (CGI) within- and between-patients), and the distribution-
based approach (comparison between the change in PRO scores and some measure 
of variability, including standard error measurement approach, standard deviation 
approach and effect size). Both methods were implemented in a longitudinal cohort 
of patients with schizophrenia. Results: 1208 patients with schizophrenia were 
included in the study, and followed for up to 2 years. The mean CDSS score at baseline 
was 2.88 (SD: 3.57), ranging from 0 to 22. MCID values obtained from the anchor-based 
approaches were 0.89 and 1.26, for within- and between-patient methods, respec-
tively, when using CGI as external criterion. MCID values obtained from the distribu-
tion-based approaches were 1.47, 1.70 and 0.71 when conducting the analysis using 
standard error measurement approach, standard deviation approach and effect size, 
respectively. ConClusions: As in many MCID analyses, although the objective is to 
provide a unique threshold value, the different methods produce a variety of MCID 
values. Nevertheless all MCID values retrieved in the present study were of the same 
order of magnitude. We therefore suggest using 1.3 as the MCID for CDSS, reflecting 
the smallest difference that clinicians would deem important. MCID estimates may 
help clinicians and researchers design future studies and interpret treatment effect.
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objeCtives: The majority of studies on depression among patients with depression 
reports means or percentages which obscure changes in depressive status over time. 
Trajectory description analysis may provide a more nuanced picture of the evolution 
of depressive status of patients. The objective of this study was to identify, in a large 
sample of patients with schizophrenia, distinct groups of patients with different 
trajectories of depressive symptoms. Methods: We used fata from a longitudinal 
observational cohort of 1208 patients with schizophrenia. Patients answered the 
Calgary Depression Scale for Schizophrenia (CDSS) questionnaire every 6 months 
for up to 2 years. Several cut-points were used, to distinguish patients with and 
without depression. Depression rates were calculated at each visit, independently, 
and depending on the patient’s previous status. Results: Rates of depression at 
the baseline visit were 39.7% and 20.2%, when considering cut-points of 3 and 6, 
respectively. Among the 477 and 243 patients considered as depressive at baseline, 
41.8% and 59.6% changed status after 6 months when considering cut-points of 3 
and of 6, respectively. Similarly, among the 724 and 958 patients considered as non-
depressive at baseline, 18.2% and 9.9% changed status after 6 months. These results 
were relatively stable over time, when considering each pair of successive visits. 
Additional analyses also showed that functioning level and quality of life paralleled 
these trajectories over time. ConClusions: Trajectory analysis allowed us to detect 
different groups of patients, with specific characteristics and different trajectories. 
Our larger sample size allowed identifying levels of various characteristics at base-
line and over time as being associated with each trajectory.
PMH7
Evolution of PrEsEncE of PrEDoMinant nEgativE syMPtoMs in 
PatiEnts witH scHizoPHrEnia
Refaï T.1, Millier A.2, Toumi M.3
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceutical, Paris, France, 3University of Marseille, 
Marseille, France
objeCtives: Patients with schizophrenia often remain symptomatic with predom-
inant negative symptoms (PNS) despite receiving antipsychotic therapy. Several 
definitions of PNS are published in the literature. The purpose of this study is to 
compare evolution of patients with and without PNS over time, and to explore 
the predictive status of PNS in terms of quality of life, depression and resource 
use, considering several definitions. Methods: Fifteen definitions of PNS were 
retrieved from literature, out of which 3 were applied in a longitudinal cohort of 
patients with schizophrenia (N= 1208). Clinical characteristics, depression, function-
ing, medication, quality of life and resource utilization were assessed at baseline 
and at 6 months, and compared between subgroups of patients (with/out PNS at 
baseline and at 6 months). Reasons of PNS status change were described for each 
definition. Regression models were used to explore the predictive status of PNS in 
terms of quality of life, depression and resource use. Results: According to the 3 
definitions used, severity of positive symptom significantly increased in patients 
with PNS at baseline but not at 6 months. Negative symptoms decreased to a lesser 
extent. Patient functioning, depression, medication, quality of life and resource 
utilization evolution were not consistent across definitions. According to all the 
definitions, PNS status at baseline was associated with change from baseline in 
terms of depression, quality of life, number of GP visits and number of hospitaliza-
tion days, when adjustments were taken into account. ConClusions: Our study 
suggests that PNS status at a specific time point is associated with depression, 
quality of life and resource utilization evolution at 6 months. Results also show that 
patients with PNS at a specific time point not showing PNS 6 months later are not 
associated with better outcomes. This confirms that schizophrenic patients with 
PNS form a severe population, and required further analyses.
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of patients with schizophrenia. Results: 1208 patients with schizophrenia were 
included in the study, and followed for 2 years. Mean GAF score at baseline was 
51.34 (SD: 16.06) ranging from 11 to 98. MCID values retrieved from the anchor-
based approaches were 2.92 and 3.8, for within- and between-patient methods, 
respectively, when using CGI as external criterion. MCID values retrieved from the 
distribution-based approaches were 9.43, 11.70 and 3.20 when conducting the analy-
sis using standard error measurement approach, standard deviation approach and 
effect size, respectively. ConClusions: As in many MCID analyses, although the 
objective is to provide a unique threshold value, the different methods produce a 
variety of MCID values. MCID values retrieved in the present study are very dispa-
rate, ranging from 2.92 to 11.70. As anchor-based measure are generally preferred 
to distribution-based measures, we suggest using 4 as the MCID for GAF, reflecting 
the smallest difference that clinicians would deem important. MCID estimates may 
help clinicians and researchers design future studies and interpret treatment effect.
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objeCtives: Clinical management of agitated patients with schizophrenia is a com-
mon objective in inpatient units and other settings. Being defined as a state char-
acterized by motor restlessness, excitement, and mental tension, agitated patients 
may become a threat to others, act out violently, and also lead to suicidal thoughts 
and behaviors. The purpose of this study is to describe the agitated schizophrenic 
population. Methods: We worked on data from a large longitudinal cohort of 
patients with schizophrenia, including a battery of questionnaires every 6 months 
for up to 24 months. Patients with a positive and negative syndrome scale (PANSS) 
Excited Component higher than 14 and a score of 4 or higher on at least one item, 
were identified as agitated at baseline. As five assessments were performed over 
2 years, pathways of agitated patients were explored. Bivariate analyses were con-
ducted to compare agitated patients with others in terms of severity of symptoms 
(PANSS), quality of life (EQ-5D), functioning (Global Assessment of Functioning, 
GAF), side effects, depression (Calgary Depression Scale for Schizophrenia, CDSS) 
and resource use. Results: 5% of patients were identified as agitated at baseline. 
This rate was very stable at 6, 12, 18 and 24 months. Agitated patients were found 
to have more severe symptoms (PANSS 95.15 vs. 55.23 p< 0.0001), lower function-
ing (GAF: 39.9 vs. 51.99 p< 0.0001), and more severe side effects (AIMS: 4.15 vs. 2.66 
p= 0.07). For each type of service, resource use was consistently higher for agitated 
patients when compared to others. No difference was found in terms of quality of 
life or depression level. ConClusions: Our study suggests that agitated patients 
with schizophrenia form a stable population overtime with a high clinical burden. 
Research on management of agitated is of key importance in schizophrenia.
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objeCtives: Medication non-adherence is common in the treatment of patients 
with severe mental illness. Different formulations have been developed in an effort to 
improve medication adherence. The aim of this study is to explore whether there is a 
differential impact on treatment discontinuation between two different formulations 
of olanzapine: orodispersible (OD) or standard oral tablets (SOT) for the treatment of 
non-adherent patients with schizophrenia or bipolar disorder. Methods: This post-
hoc analysis included 266 non-adherent patients diagnosed either with schizophrenia 
or bipolar disorder from an observational study (n= 927) that measured the proportion 
of patients who discontinued treatment for any reason with olanzapine OD or SOT 
formulations over a 1-year period. Non-adherence was defined as having a baseline 
rating from 0 to 4 in the Medication Adherence Rating Scale (MARS). Treatment dis-
continuation was defined as discontinuing or adding a new antipsychotic to the index 
medication. A Kaplan Meier estimation of time to medication discontinuation was 
calculated. A Cox regression model adjusting for covariates was fitted to study the 
effect of baseline treatment on time to discontinuation. Results: Patients treated 
with OD (n= 177) vs. SOT (n= 89) were more severe as measured by the Clinical Global 
Impression scale (CGI) (4.63 [SD 1.03] vs. 4.0 [SD 1.16], p < 0.0001) at baseline. During 
the 1-year follow up period the Kaplan Meier graph showed that patients treated with 
OD were less likely to discontinue treatment (11% vs. 27%, p< 0.01). The Cox regression 
showed that patients taking OD had a significantly lower risk of discontinuing their 
baseline medication compared to patients taking SOT (hazard ratio: 0.35; 95% CI: 
0.15-0.80). ConClusions: Treatment discontinuation was low with both olanzapine 
formulations; however the use of the orodispersible formulation in non-adherent 
patients with schizophrenia or bipolar disorder was associated with a significantly 
lower treatment discontinuation rate over a 1-year period.
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objeCtives: No Minimum Clinically Important Difference (MCID) for the Calgary 
Depression Scale for Schizophrenia (CDSS) has been reported yet. This scale, ranging 
from 0 to 27, assesses the level of depression in schizophrenia. The objective of this 
study was to generate a MCID for the CDSS, based on a longitudinal cohort of patients 
